European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 

Arterial Hypertension (Management of)

ESH/ESC Clinical Practice Guidelines

Topics: Hypertension

14/06/2013 00:00:00

Current versions available to download

Publication dateVersionsReferencesSize
2013Essential Messages997 KB
2013Full TextEuropean Heart Journal:34;2159–2219
2013 Summary Card449 KB
2013Pocket Guidelines
  Slide-setSlides on Arterial Hypertension 201314 MB
2013CME Questions

Current translated versions available to download:

Authors

Guiseppe Mancia (Chairperson)(Italy), Robert Fagard (Chairperson) (Belgium), Krzysztof Narkiewicz (Poland), Josep Redon (Spain), Alberto Zanchetti (Italy), Michael Böhm (Germany), Thierry Christiaens (Belgium), Renata Cifkova (Czeck Republic), Guy De Backer (Belgium), Anna Dominiczak (UK), Maurizio  Galderisi (Italy), Diederick E. Grobbee (Netherlands), Tiny Jaarsma (Sweden), Paulus Kirchhof (Germany/UK), Sverre E. Kjeldsen (Norway), Stéphane Laurent (France), Athanasios J. Manolis (Greece), Peter M Nilsson (Sweden), Luis Miguel Ruilope (Spain), Roland E. Schmieder (Germany), Per Anton Sirnes (Norway), Peter Sleight (UK), Margus Viigimaa (Estonia), Bernard Waeber (Switzerland), Faiez Zannad (France).

Declarations of Interest of the experts involved in the elaboration of the document.

Endorsed by:

Table of contents: Full Text (ESC Clinical Practice Guidelines)

1.Introduction
2.Epidemiological aspects
    2.1. Relationship of blood pressure to CV & renal damage
    2.2.Definition & classification of hypertension
    2.3.Prevalence of hypertension
    2.4.Hypertension & total CV risk
3.Diagnostic evaluation
    3.1.Blood pressure measurement
    3.2.Medical therapy
    3.3.Physical examination
    3.4.Summary of recommendations on measurements, history & physical examination
    3.5.Laboratory investigations
    3.6.Genetics
    3.7.Searching for asymptomatic organ damage
    3.8.Searching for secondary forms of hypertension
4.Treatment approach
    4.1.Evidence favouring therapeutic reduction of high blood pressure
    4.2.When to initiate anihypertensive drug treatment
    4.3.Blood pressure treatment targets
5.Treatment strategies
    5.1.Lifestyle changes
    5.2.Pharmacological therapy
6.Treatment strategies in special conditions
    6.1.White-coat hypertension
    6.2.Masked hypertension
    6.3.Elderly
    6.4.Young adults
    6.5.Women
    6.6.Diabetes mellitus
    6.7.Metabolic syndrome
    6.8.Obstructive sleep apnoea
    6.9.Diabetic & non diabetic nephropthy
    6.10.Cerebrovascular disease
    6.11.Heart Disease
    6.12.Atherosclerosis, & PAD
    6.13.Sexual dysfunction
    6.14.Resistant hypertension
    6.15.Malignant hypertension
    6.16.Hypertensive emergencies & urgencies
    6.17.Perioperative management of hypertension
    6.18.Renovascular hypertension
    6.19.Primary aldosteronism
7.Treatment of associated risk factors
    7.1.Lipid lowering agents
    7.2.Antiplatelet therapy
    7.3.Treatment of hyperglycaemia
    7.4.Summary of recommendations on treatment of risks factors associated with hypertension
8.Follow-up
    8.1.Follow-up of hypertensive patients
    8.2.Follow-up of subjects with high normal blood pressure & white-coat hypertension
    8.3.Elevated blood pressure at control visits
    8.4.Continued search for asymptomatic organ damage
    8.5.Can antihypertensive medications be reduced or stopped?
9.Improvement of blood pressure control in hypertension
10.Hypertension disease management
    10.1.Team approach in disease management
    10.2.Mode of care delivery
    10.3.The role of information & communication technologies
11.Gaps in evidence & need for future trials


    
    

Previous versions

YearJournal ReferencesDocument
2003J Hypertension21:1011-1053
2007Eur Heart J28:1462-1536